On Tuesday, Illumina laid out a three-year plan for investors detailing how the struggling DNA sequencing company plans to get back to growth. To do so, its CEO said, the company is making it easier for customers to derive and interpret biological insights.
CEO Jacob Thaysen and Chief Technology Officer Steven Barnard spoke with Endpoints News after the company’s presentation, going into more depth on their plan to reinvigorate the company, which over the last 18 months has experienced high executive turnover and flat growth. The period has been a dour contrast to the company’s earlier history as a scientific and market darling.
Steven Barnard
By 2027, the company projects that its revenue growth will reach the “high single digits.”
“We actually have a pretty good line of sight of how we’re going to get back to growth,” Thaysen said. But he’ll have to do so as the company cuts
